Linagliptin Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 5 mg

Reference Brands: Tradjenta®(EU & US)

Category: Diabetes

Linagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing insulin secretion and lowering glucagon in a glucose-dependent manner. Benefits include improved glycemic control, low hypoglycemia risk, once-daily dosing, and weight neutrality. Approved in both the USA and EU, it's suitable as monotherapy or in combination therapy. Linagliptin Tablets is available in Tablets and strengths such as 5 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Linagliptin Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Linagliptin Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Linagliptin tablets are approved for the treatment of type 2 diabetes in both the USA and EU. In the USA, they are marketed as Tradjenta®, approved via a New Drug Application (NDA) and regulated under 21 CFR, with labeling for risks like pancreatitis and joint pain. Manufacturers must ensure GMP compliance and implement post-marketing surveillance. In the EU, Linagliptin is authorized as Trajenta® via the centralized procedure, requiring CTD-format submission, a Risk Management Plan (RMP), PSURs, and full pharmacovigilance. For regulatory support, dossier preparation, or B2B sourcing, visit PharmaTradz.com.